[Translated article] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma
Nivolumab in the treatment of relapsed or refractory classical Hodgkin's lymphoma has confirmed favourable effectiveness data in the study sample, expressed as objective response rate of 46.2% and a clinical benefit rate of 69.2%. Safety was acceptable, manageable, and consistent with that described in the literature.
Authors
- Laura Lorente Fernández
- Eduardo López Briz (ORCID: https://orcid.org/0000-0002-6519-522X)
- Samuel Romero Domínguez
- Asunción Albert Marí (ORCID: https://orcid.org/0000-0002-3814-2341)
- Esperanza Núñez Benito
- Jose Luís Poveda Andrés
Institutions
- Generalitat Valenciana (ES)
- Hospital Universitari i Politècnic La Fe (ES)
Publication Details
- Journal
- Farmacia Hospitalaria
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1016/j.farma.2024.09.006
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00